International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Tóm tắt
Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.
Từ khóa
Tài liệu tham khảo
Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes., Br J Haematol, 51, 189, 10.1111/j.1365-2141.1982.tb08475.x
Mufti, 1985, Myelodysplastic syndromes: A scoring system with prognostic significance., Br J Haematol, 59, 425, 10.1111/j.1365-2141.1985.tb07329.x
Sanz, 1989, Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients., Blood, 74, 395, 10.1182/blood.V74.1.395.395
Aul, 1992, Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system., Leukemia, 6, 52
Morel, 1993, Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases., Leukemia, 7, 1315
Toyama, 1993, Clinical implications of chromosomal abnormalities in 401 patients with MDS: A multicentric study in Japan., Leukemia, 7, 499
Oscier, 1987, Myelodysplastic syndromes., Ballieres Clin Haematol, 1, 389, 10.1016/S0950-3536(87)80007-0
Tricot, 1985, The myelodysplastic syndromes: Different evolution patterns based on sequential morphological and cytogenetic investigations., Br J Haematol, 59, 659, 10.1111/j.1365-2141.1985.tb07361.x
Rios, 1990, Bone marrow biopsy in myelodysplastic syndromes: Morphological characteristics and contribution to the study of prognostic factors., Br J Haematol, 75, 26, 10.1111/j.1365-2141.1990.tb02612.x
Jacobs, 1986, Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes., Blood, 67, 1765, 10.1182/blood.V67.6.1765.bloodjournal6761765
Yunis, 1988, Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia., Br J Haematol, 68, 189, 10.1111/j.1365-2141.1988.tb06188.x
Pierre, 1990, Clinical cytogenetic correlations in myelodysplasia (preleukemia)., Cancer Genet Cytogenet, 44, 15
Bennett, 1994, The chronic myeloid leukemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia., Br J Haematol, 87, 746, 10.1111/j.1365-2141.1994.tb06734.x
Coiffier, 1983, Dysmyelopoietic syndromes: A search for prognostic factors in 193 patients., Cancer, 52, 83, 10.1002/1097-0142(19830701)52:1<83::AID-CNCR2820520117>3.0.CO;2-9
Tricot, 1985, Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis., Br J Haematol, 60, 19, 10.1111/j.1365-2141.1985.tb07381.x
Vallespi, 1985, A study of 101 cases according to the FAB classification., Br J Haematol, 61, 83, 10.1111/j.1365-2141.1985.tb04063.x
Kerkhofs, 1987, Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases., Br J Haematol, 65, 73, 10.1111/j.1365-2141.1987.tb06138.x
Foucar, 1985, Myelodysplastic syndromes: A clinical and pathologic analysis of 109 cases., Cancer, 56, 553, 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q
Wattel, 1993, De novo myelodysplastic syndrome with deletion of the long arm of chromosome 20: A subtype of MDS with distinct hematological and prognostic features?, Leuk Res, 17, 921, 10.1016/0145-2126(93)90038-M
Campbell, 1994, The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders., Leukemia, 8, 67
Sokal, 1975, A new hematologic syndrome with a distinct karyotype: The 5q− chromosome., Blood, 46, 519, 10.1182/blood.V46.4.519.bloodjournal464519
Van den Berghe, 1985, The 5q− anomaly., Cancer Genet Cytogenet, 17, 189, 10.1016/0165-4608(85)90016-0
United, 1992, Loss of the Y chromosome from normal and neoplastic bone marrows., Genes Chromosome Cancer, 5, 83, 10.1002/gcc.2870050112
Samuels, 1988, Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo., Leukemia, 2, 79
Morel, 1996, Prognostic factors in myelodysplastic syndromes: Critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques., Br J Haematol, 94, 116, 10.1046/j.1365-2141.1996.6122056.x
Storniolo, 1990, Chronic myelomonocytic leukemia., Leukemia, 4, 766